clinical trial · NCT06704009
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
NexThera Co., Ltd.·phase2·active not recruiting·n = 30
Wet Age Related Macular DegenerationWet AMDNT-101 Low DoseNT-101 High Dose
brief summary
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
started
Mar 11, 2025
primary completion
Dec 15, 2025
completion
May 1, 2026
last updated
Apr 8, 2026
official title
A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol